Last week was another week packed full of reasons to be excited developments in the biotech space, with some HUGE news in obesity, immunology, HIV, vaccines and more. Enjoy another week of the best news in biotech…
-
Altimmune, Inc.
touted "best-in-class" weight loss while preserving lean mass data in a phase 2 obesity study Link
-
Gilead Sciences
' twice yearly HIV prevention drug showed 100% efficacy in a phase 3 trial Link
- The FDA approved
Merck
's Capvaxive as the world's first pneumococcal disease vaccine designed for adults Link
-
Innovent Biologics
' bispecific immuno-oncology candidate IBI363 has been linked to a 100% response rate in a small cohort of Chinese lung cancer patients in a phase 1 trial Link
-
Johnson & Johnson
's phase 2 Sjögren's data suggest that it is are on the right track by targeting FcRn antagonism at the automimmune disorder Link
-
Roche
's Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma Link
-
Taysha Gene Therapies
published positive clinical data from a phase 1/2 Rett Syndrome gene therapy study Link
-
AbbVie
's IL-23 inhibitor Skyrizi gains approval in its 4th disease, ulcerative colitis Link
- Also in IL-23,
Johnson & Johnson
's guselkumab delivered positive results in a phase 3 subcutaneous injection trial for Crohn's disease Link
-
Intra-Cellular Therapies
' antipsychotic Caplyta had another win with outstanding phase 3 results treating major depressive disorder Link
- Long term data for
Vertex Pharmaceuticals
&
CRISPR Therapeutics
CASGEVY™ demonstratef transformative, consistent and durable benefit Link
-
Roche
partnered with
Ascidian Therapeutics
in a deal worth $42M upfront and up to $1.8B in milestone payments to develop exon editing drugs Link
-
Belharra Therapeutics
announced a $40M upfront and up to $700M biobucks collaboration with
Sanofi
to identify and advance small molecules against Sanofi-designated immunology targets Link
-
Day One Biopharmaceuticals
is paying Mabcare $55M upfront and up to $1.2B in biobucks for exclusive ex-China licensing rights to an ADC for solid tumors Link
- Melodia Therapeutics has signed a $275 million biobucks deal with
Alivexis, Inc
for development and commercialization rights to MDI-0151, a novel Cathepsin C inhibitor with best-in-class potential for various refractory inflammatory diseases Link
-
J.P. Morgan
Life Sciences Private Capital closed its inaugural biotech VC fund with over $500m to invest in private biotechnology companies across stage, modality, therapeutic area, and geography Link
-
Marea Therapeutics
, incubated by
Third Rock Ventures
launched with $190M and a clinical-stage pipeline of first in class cardiometabolic disease treatments Link
-
Iambic Therapeutics
raised a $50M series B extension to broaden its pipeline of AI-discovered clinical oncology programs Link
-
Elion Therapeutics
completed an $81M series B to advance its clinical stage anti-fungal pipeline Link
-
InduPro
raised an $85M series A to advance a cancer and autoimmune biologics pipeline to clinic Link
-
iOnctura
announced an $85M series B led by
Syncona Limited
to progress a number of early clinical first-in-class oral therapeutics against hard to treat cancers Link
-
Syncona Limited
lso launched Yellowstone Biosciences with £16.5M to develop soluable bispecific TCR-based therapies for cancer Link
In an industry first… Professor
Daniel Siegwart
and his team at
UT Southwestern Medical Center
, in a collaboration with
ReCode Therapeutics
, developed an LNP delivery technology that can effectively deliver to lung stem cells and yield durable gene editing responses. Intravenously administered gene-editing LNPs achieved >70% lung stem cell editing, sustaining expression in >80% of lung epithelial cells for 660 days in-vivo. Great paper
Yehui Sun
, a potential game changer for CF and other genetic lung disease patients! Full paper
That's all for this week. Subscribe for alerts to the latest positive news in the industry ⬇️🔔
About the author: Max Robinson is an ex-scientist turned talent leader in the biotechnology industry, and currently Global Head of Discovery & Preclinical Research at Proclinical.
